Intranasal Insulin

Phase 2Small molecule

UUniversity Health Network, Toronto

Intranasal Insulin is one of 67 small molecule programs targeting Cognitive Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive DisorderActive, not recruiting

Insulin SecretionActive, not recruiting

Alzheimer DiseaseRecruiting

Cognitive DisorderPreclinical

Active, not recruiting

Insulin SecretionPreclinical

Active, not recruiting

Alzheimer DiseasePhase 2

Recruiting

Competition

Competitive Landscape

100 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

Niacor

Victoza

Lexapro

Calciferol

Azilect

Neupro

Evista

Celebrex

PPhiladelphia Eye Associates

Approved

1 9

Kisunla

Eli Lilly

Phase 3

4 10

Lithobid

SSolvay Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Alzheimer Disease

NCT06072963

Q1 2029

N/ANot yet recruiting

Psychosis

NCT07252752

Q2 2029

PreclinicalRecruiting

Type 2 Diabetes

NCT07675499

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes

Completed·—·Phase 2·NCT01206322·30 enrolled

Effects of Intranasal Insulin Plus Exercise Training on Brain Blood Flow, Neuronal Insulin Signaling, and Cognition in Adults With Type 2 Diabetes

Recruiting·RRutgers, The State University of New Jersey·Preclinical·NCT07675499·60 enrolled

Schizophrenia2 trials

Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia

Recruiting·CCentre for Addiction and Mental Health·N/A·NCT05748990·20 enrolled

Evaluation Study of New Compounds With Potential Use in Schizophrenia

Withdrawn·—·Phase 1·NCT00916201

Post Operative Cognitive Dysfunction2 trials

Effect of Intranasal Insulin on Postoperative Cognitive Dysfunction

Unknown status·MMinia University··NCT04154449·57 enrolled

Pre-operative Intra-nasal Dexmedetomidine or Insulin for Prevention of Early Post-operative Cognitive Dysfunction in Patients Undergoing Elective Coronary Artery Bypass Graft. A Comparative Randomized Bi-centric Study

Completed·MMinia University·Phase 1·NCT06741566·150 enrolled

Psychosis2 trials

Dopamine and Insulin in Psychosis

Not yet recruiting·MMedical University of Vienna·N/A·NCT07252752·46 enrolled

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

Completed·MMclean Hospital·Phase 2·NCT03943537·87 enrolled

Insulin resistance1 trial

Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance

Completed·UUniversity Health Network, Toronto·Phase 1/2·NCT03383822·7 enrolled

19 more indications

AIN1 trial

Regulation of Endogenous Glucose Production by Brain Insulin Action

Completed·UUniversity Health Network, Toronto·Phase 1·NCT02131948·8 enrolled

Multiple System Atrophy1 trial

Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.

Completed·PPeter Novak·Phase 2·NCT02064166·15 enrolled

Completed·FFlorian Schmitzberger·Phase 1·NCT06144255·6 enrolled

Insulin Sensitivity1 trial

"Effect of Central Insulin Administration on Whole-body Insulin Sensitivity in Women"

Completed·UUniversity Hospital Tuebingen·N/A·NCT03929419·29 enrolled

Efficacy1 trial

Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome

Completed·AAjna Hamidovic·Phase 2·NCT01781234·51 enrolled

Bipolar Disorder1 trial

The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder

Completed·UUniversity Health Network, Toronto·Phase 3·NCT00314314·60 enrolled

Concentration1 trial

Effect of Intranasal Insulin on LH Concentrations in Man

Completed·TTexas Tech University Health Sciences Center·Phase 1/2·NCT02154477·14 enrolled

Trial1 trial

PINIT Study: Primary Intranasal Insulin Trial

Completed·TTechnical University of Munich·Phase 2·NCT03182322·38 enrolled

Insulin Secretion1 trial

Influence of Central Nervous Insulin Sensitivity on Insulin Secretion

Completed·UUniversity Hospital Tuebingen·N/A·NCT02870361·15 enrolled

Cognition1 trial

Intranasal Insulin and Post-stroke Cognition: A Pilot Study

Completed·WWake Forest University Health Sciences·Phase 2·NCT02810392·20 enrolled

ESS1 trial

Effect of Intranasal Insulin on Cognitive Processes and Appetite

Completed·UUniversity of Birmingham·N/A·NCT03632681·64 enrolled

ART1 trial

Dose-Finding Study of Intranasal Insulin in Healthy Participants Insulin in Healthy Participants

Completed·RRobert Silbergleit·Phase 1·NCT05062785·24 enrolled

Smoking Cessation1 trial

Intranasal Insulin for Weight Management During Smoking Cessation

Completed·AAjna Hamidovic·Phase 2·NCT02028871·26 enrolled

Type 1 Diabetes1 trial

Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes

Completed·MMelbourne Health·Phase 2·NCT00336674·110 enrolled

Treatment1 trial

Intranasal Insulin: A Novel Treatment for Gulf War Multisymptom Illness

Unknown status·BBronx Veterans Medical Research Foundation, Inc·Phase 2·NCT01802944·114 enrolled

Alzheimer disease1 trial

Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study

Recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT06072963·80 enrolled

PTSD1 trial

Intranasal Insulin for Treating Posttraumatic Stress Disorder

Completed·VVA Connecticut Healthcare System·Phase 2·NCT04044534·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 28 trial records for Intranasal Insulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intranasal Insulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intranasal Insulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Health Network, Toronto company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Health Network, Toronto

Intranasal Insulin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2029

Q2 2029

Trials by Indication[1]

Type 2 Diabetes2 trials

Schizophrenia2 trials

Post Operative Cognitive Dysfunction2 trials

Psychosis2 trials

Insulin resistance1 trial

AIN1 trial

Multiple System Atrophy1 trial

Memory1 trial

Cognitive Disorder1 trial

Magnetic Resonance Imaging1 trial

Insulin Sensitivity1 trial

Efficacy1 trial

Bipolar Disorder1 trial

Concentration1 trial

Trial1 trial

Insulin Secretion1 trial

Cognition1 trial

ESS1 trial

ART1 trial

Smoking Cessation1 trial

Type 1 Diabetes1 trial

Treatment1 trial

Alzheimer disease1 trial

PTSD1 trial

References

Drug Info

Quick Facts

Related News